
Merck KGaA
MRK.DE
Updated: 23/09/2026, 04:10:49
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
No summaries found.
- Share price
- €133.15
- Market cap
- €57.85B
- Exchange
- XETRA
- Currency
- EUR
- CEO
- Kai Beckmann
- Employees
- 62,136
- IPO date
- 26/06/1998
- Beta
- 0.805
- Last dividend
- €0.00
- Day range
- €132.10 – €134.00
- 52-week range
- €100.70 – €148.80
- 1-day performance
- 0.41%
- 1-year performance
- 32.22%
- Current drawdown (1Y)
- -10.52%
- CIK
- N/A
- CUSIP
- D5357W103
- ISIN
- DE0006599905
- Created
- 07/09/2026, 05:15:42
- Last update
- 23/09/2026, 04:10:49
Track Merck KGaA with an AI analyst
See which prediction-market events move MRK.DE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.